Serotonin syndrome after sertraline buspirone and loxapine? [2]

Therapie

Volumn 54, Issue 2, 1999, Pages 269-271

  Bonin, B ^a   Vandel, P ^a   Vandel, S ^b   Sechter, D ^a   Bizouard, P ^a  

^a UNIVERSITY HOSPITAL OF BESANÇON   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BUSPIRONE; LOXAPINE; SERTRALINE;

ADULT; CASE REPORT; DEPRESSION; HUMAN; LETTER; MALE; PRIORITY JOURNAL; SEROTONIN SYNDROME;

ANTI-ANXIETY AGENTS; ANTIPSYCHOTIC AGENTS; BUSPIRONE; DOPAMINE ANTAGONISTS; DRUG THERAPY, COMBINATION; HUMANS; LOXAPINE; MALE; MIDDLE AGED; SEROTONIN SYNDROME; SEROTONIN UPTAKE INHIBITORS; SERTRALINE;

EID: 0033025811     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (21)

1. Martin P, Guillou N, Lacroix P, Billardon M. Effets d'une coadministration d'antidépresseur et d'anxiolytique dans le paradigme de 'learned-helplessness': intérêt de l'hydroxyzine. L'Encephale 1996; XXII: 270-279.
2. Sternbach H. The serotonin syndrome. Am J Psychiatry 1991; 148: 705-713.
3. Price WA, Zimmer B, Kucas P. Serotonin syndrome: a case report. J Clin Pharmacol 1986; 26: 77-78.
4. Pearlman CA. Neuroleptic malignant syndrome: a review of the literature. J Clin Psychopharmacol 1986; 6: 257-273.
5. Caroff SN. The neuroleptic malignant syndrome. J Clin Psychiatry 1980; 41: 79-83.
6. Hjorth S, Carlsson A. Buspirone: effects on central monoaminergic transmission-possible relevance to animal experimental and clinical findings. Eur J Pharmacol 1982; 83: 299-303.
7. Neppe VM. The clinical neuropharmacology of buspirone. In: Neppe VM, ed. Innovative Psychopharmacotherapy. New York: Raven 1989: 35-57.
8. Baumann P, Bertschy G. Pharmacodynamic and pharmacokinetic interactions of selective serotonin re-uptake inhibiting antidepressants (SSRIs) with other psychotropics drugs. Nord J Psychiatry 1993; 47: 13-19.
9. Lejoyeux M, Rouillon F, Ades J. Prospective evaluation of the serotonin syndrome in depressed inpatients treated with clomipramine. Acta Psychiatr Scand 1993; 88: 369-371.
10. Lenzi A, Raffaelli S, Marazziti D. Serotonin syndrome-like symptoms in a patient with obsessive-compulsive disorder, following inappropriate increase in fluvoxamine dosage. Pharmacopsychiatry 1993; 26: 100-101.
11. Skop BP, Finkelstein JA, Maretti TR et al. The serotonin syndrome associated with paroxetine, an over-the-counter cold remedy. Am J Emergency Med 1994; 12: 642-644.
12. Lane R, Fischler B. The serotonin syndrome: coadministration, discontinuation and washout periods for the selective serotonin reuptake inhibitors (SSRIs). J Serotonin Res 1995; 3: 171-180.
13. Brown TM, Skop BP, Mareth TR. Pathophysiology and management of the serotonin syndrome. Ann Pharmacother 1996; 30: 527-533.
14. Sobanski T, Bagli M, Laux G, Rao ML. Serotonin syndrome after lithium add-on medication to paroxetine. Pharmacopsychiatry 1997; 30: 106-107.
15. Steiner W, Fontaine R. Toxic reaction following the combined administration of fluoxetine and 1-tryptophane: five case reports. Biol Psychiatry 1986; 21: 1067-1071.
16. Rosenblatt JE, Rosenblatt NC. How long a hiatus between discontinuing fluoxetine and beginning sertraline. Curr Affective Illness 1992; 11:2.
17. Brannan SK, Talley BJ, Bowden CL. Sertraline and isocarboxazid cause a serotonin syndrome. J Clin Psychopharmacol 1994; 14: 144-145.
18. Graber MA, Hoehns TB, Perry PJ. Sertraline-phenelzine drug interaction: a serotonin syndrome reaction. Ann Pharmacotherapy 1994; 28: 732-735.
19. Goldberg RJ, Huk M. Serotonin syndrome from trazodone and buspirone (letter). Psychosomatics 1992; 2: 235.
20. Kline SS, Mauro LS, Scala-Barnett DM, Zick D. Serotonin syndrome versus neuroleptic malignant syndrome as a cause of death. Clin Pharm 1997; 8: 510-514.
21. Begaud B, Evreux JC, Joughlard J, Lagier G. Imputabilite des effets inattendus ou toxiques des médicaments. Therapie 1985; 40: 111-118.